The International, Prospective COSMOS (CytOSorb® TreatMent Of Critically Ill PatientS) Registry: Interim Results in Patients with Septic Shock

Ricard Ferrer Roca, Thomas Kirschning, Moritz Unglaube, Ulf Guenther, Julian Kreutz, Matthias Thielmann, Andreas Baumann, Andreas Kribben, Dietrich Henzler, Nuno Germano, Aschraf El-Essawi, Filippo Aucella, Thomas Guenther, Martin Bellgardt, Bartosz Tyczynski, P. Christian Schulze, Gabriella Bottari, Jorge Hidalgo, Jean Louis Teboul, Dana Tomescu, Teresa Klaus, Weihong Fan, Joerg Scheier, Efthymios Deliargyris and Fabio Silvio Taccone

ULB Institutional Repository from ULB -- Universite Libre de Bruxelles

Abstract: Background The international prospective COSMOS Registry (NCT05146336) collects real-world data on CytoSorb® (CS) hemoadsorption utilization patterns and outcomes in critically ill patients. This analysis focuses on patients with septic shock. Methods Following informed consent, data was systematically collected before, during, and after CS treatment. Time frame of data collection was from the initiation of COSMOS study enrollment (July 15, 2022) to date of data extraction (May 7, 2025). Study follow-up extended to 90 days. We compared details on vasopressor requirements, fluid balance, and P/F ratio before and after CS treatment. APACHE II was assessed at ICU admission, while SOFA scores were determined at the start and end of CS therapy. Safety of the device was assessed based on investigator-reported device-related adverse effects. Data are presented as either mean ± standard deviation or as median with interquartile ranges (IQR). Results A total of 140 patients (mean age of 61 ± 15 years, 33% female) at 18 study sites treated for septic shock was analyzed. On admission, median APACHE II score was 24 [18,30], SOFA score was 13 [11,15] and Charlson scores of 4 [2,6]. CS therapy was applied as part of kidney replacement therapy (KRT, 85%), standalone hemoperfusion (10%) or extracorporeal membrane oxygenation (ECMO, 5%). On average, each patient received 2.8 ± 2.2 adsorbers, with 47% receiving three or more. CS therapy was associated with a significant reduction in interleukin (IL)-6 levels (from 2,013 [219, 39,988] to 108 [75, 1,662] pg/mL, p

Keywords: Adsorption; Blood purification; CytoSorb; Hemoadsorption; Hemoperfusion; Hyperinflammation; Registry; Sepsis; Septic shock (search for similar items in EconPapers)
Date: 2026-01
Note: SCOPUS: ar.j
References: Add references at CitEc
Citations:

Published in: Annals of intensive care (2026) v.16

Downloads: (external link)
https://dipot.ulb.ac.be/dspace/bitstream/2013/412142/1/doi_395786.pdf Full text for the whole work, or for a work part (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ulb:ulbeco:2013/412142

Ordering information: This working paper can be ordered from
http://hdl.handle.ne ... lb.ac.be:2013/412142

Access Statistics for this paper

More papers in ULB Institutional Repository from ULB -- Universite Libre de Bruxelles Contact information at EDIRC.
Bibliographic data for series maintained by Benoit Pauwels ().